Vor Biopharma Inc (VOR)
Vor Biopharma Inc. is a clinical-stage cell and genome engineering company focused on developing therapies for acute myeloid leukemia and other blood cancers. Its main platform, the Vor Bio platform, supports a pipeline that includes tremtelectogene empogeditemcel, or trem-cel, a genome-edited allogeneic stem and progenitor cell product candidate being studied for AML, myelodysplastic syndrome, and related blood cancers. The company is also evaluating trem-cel with Mylotarg in the phase 1/2 VBP101 study, while its VCAR33 program is a preclinical CAR-T therapy designed to target CD33 in AML after transplant. Additional preclinical programs include trem-cel plus VCAR33, VADC45 for hematologic malignancies, conditioning and immune reset, and a CD33-CLL1 treatment system based on multiplex-edited HSC and multi-specific CAR-T approaches. Vor Biopharma was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | P/E Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-VOR
|
$17.11
|
-20.0% Downside
|
Overvalued
|
$39
|
82.2% Upside
|
Bargain
|
Fair
|
0.0%
|
November 11, 2026
|
2.0x
|
1.266 B
|
802.8 M
|
0.2%
|
62.9%
|
-2.7
|
-22.4%
|
